Statements (24)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
DVS Sciences
|
| gptkbp:focus |
clinical research
life sciences research |
| gptkbp:founded |
1999
|
| gptkbp:founder |
gptkb:Stephen_Quake
gptkb:Gajus_Worthington |
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Fluidigm Corporation
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:keyPerson |
gptkb:Chris_Linthwaite
|
| gptkbp:numberOfEmployees |
~600 (as of 2021)
|
| gptkbp:product |
single-cell genomics
mass cytometry microfluidic systems |
| gptkbp:renamed |
Standard BioTools Inc.
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
FLDM
|
| gptkbp:tradedOn |
gptkb:NASDAQ:FLDM
|
| gptkbp:website |
https://www.fluidigm.com/
|
| gptkbp:bfsParent |
gptkb:Carl_W._Hull
gptkb:Chris_Linthwaite gptkb:NASDAQ:FLDM |
| gptkbp:bfsLayer |
8
|